Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label,Dose-escalation Study to Evaluate the Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

NCT06819514 is registered in ClinicalTrials.gov with Guangzhou Jiayin Biotech Ltd as lead sponsor.

NCT NCT06819514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06819514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label,Dose-escalation Study to Evaluate the Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
Lead sponsor
Guangzhou Jiayin Biotech Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 1, 2025
Completion date
March 15, 2028
Enrollment
16 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease